Evidence map›Paper›PMID 42319640›Full record

ReviewJournal of natural medicines2026

Matrine and oxymatrine: a comprehensive review of multitarget mechanisms and therapeutic potential.

Mingxi Xiang, Luwei Tian, Shiyun Lu, Jiayi Guo, Yan Chen, Xiangchun Shen, Ronggui Qin, Changyan Xu, Yini Xu, Di Pan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mingxi Xiang *The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province/Key Laboratory of Novel Anti-Cancer Drug Targets Discovery and Application, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, 561113, China.
Luwei Tian *The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province/Key Laboratory of Novel Anti-Cancer Drug Targets Discovery and Application, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, 561113, China.
Shiyun Lu *The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province/Key Laboratory of Novel Anti-Cancer Drug Targets Discovery and Application, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, 561113, China.
Jiayi GuoThe High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province/Key Laboratory of Novel Anti-Cancer Drug Targets Discovery and Application, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, 561113, China.
Yan ChenThe High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province/Key Laboratory of Novel Anti-Cancer Drug Targets Discovery and Application, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, 561113, China.
Xiangchun ShenThe High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province/Key Laboratory of Novel Anti-Cancer Drug Targets Discovery and Application, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, 561113, China.
Ronggui QinThe High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province/Key Laboratory of Novel Anti-Cancer Drug Targets Discovery and Application, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, 561113, China.
Changyan XuThe High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province/Key Laboratory of Novel Anti-Cancer Drug Targets Discovery and Application, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, 561113, China.
Yini XuThe High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province/Key Laboratory of Novel Anti-Cancer Drug Targets Discovery and Application, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, 561113, China. 605446623@qq.com.
Di PanThe High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province/Key Laboratory of Novel Anti-Cancer Drug Targets Discovery and Application, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, 561113, China. pandipharm@126.com.

Funding

Program of the National Science Foundation of China 82304556;82460488
6 · The paper itself

Abstract

In recent years, research of matrine (MAT) and oxymatrine (OMT) has shifted from merely discovering pharmacological activities to exploring mechanisms, expanding new indications, and improving formulations. However, comparative analyses of their similarities and differences remain limited. Beyond their well-known functions in cancer treatment-such as regulating non-coding RNAs, preventing metastasis, and triggering apoptosis and ferroptosis-these compounds also show notable immunomodulatory effects, particularly in synergizing with immune checkpoint inhibitors to enhance tumor responsiveness. Furthermore, they show efficacy in inflammatory and autoimmune diseases (e.g., colitis, psoriasis, encephalomyelitis), neuroprotection, cardioprotection, and anti‑fibrosis. To overcome limitations such as hepatotoxicity and poor bioavailability, significant progress has been made in the structural modification of MAT and in the advanced formulation of OMT, thereby enhancing potency, selectivity, and targeted delivery. This review systematically consolidates recent advances in their multitarget mechanisms and expanding their therapeutic landscape. It also provides a unified mechanism overview and highlights the transformation strategy. These collective efforts will improve our understanding of MAT and OMT, offering a valuable reference for the further development of these natural products into modern therapeutics.

Indexed as

AlkaloidsQuinolizinesAnimalsHumansMatrinesAlkaloidsMatrinesoxymatrineQuinolizinesDrug deliveryFerroptosisImmunomodulationMatrineNatural productsOxymatrine

Identifiers

PMID42319640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.